Tenaya Therapeutics Inc (TNYA NASDAQ) stock market data APIs
$0.9534
0.01(1.1%)
as of March 9, 2026
Try our APIs with
free plan!
Tenaya Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. The company has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. for discovering novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Prev. Close
0.9534
Open
0.9553
High
1.0419
Low
0.8133
52 wk Range
0.36-2.35
Market Cap
207 M
Shares Outstanding
217 M
EPS
-0.12
Beta
3.225
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tenaya Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tenaya Therapeutics Inc data using free add-ons & libraries
Get Tenaya Therapeutics Inc Fundamental Data
Tenaya Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -88 510 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.15
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tenaya Therapeutics Inc News
New
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-30...
Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi ...
Tenaya Enters Research Collaboration With Alnylam; To Receive Up To $10 Mln In Upfront Payments
(RTTNews) - Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY), to discover human genetic targets for the potential development of disease-modi...
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Tenaya Therapeutics, Inc. Agreement Combines Tenaya’s Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics ...
Get Tenaya Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
